Data from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AbstractPurpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combination with endocrine therapy. We explored the efficacy of palbociclib in patients with nonbreast solid tumors containing an amplification in CCND1, 2, or 3. Patients and Methods: Patients with tumors containing a CCND1, 2, or 3 amplification and expression of the retinoblastoma protein were assigned to subprotocol Z1B and received palbociclib 125 mg once daily for 21 days of a 28-day cycle. Tumor response was assessed every two cycles. Results: Forty patients were assigned to subprotocol Z1B; 4 patients had outside assays identifying the CCND1, 2, or 3 amplification and were not confirmed centrally; 3 were ineligible and 2 were not treated (1 untreated patient was also ineligible), leaving 32 evaluable patients for this analysis. There were no partial responses; 12 patients (37.5%) had stable disease as best response. There were seven deaths on study, all during cycle 1 and attributable to disease progression. Median progression-free survival was 1.8 months. The most common toxicities were leukopenia (n = 21, 55%) and neutropenia (n = 19, 50%); neutropenia was the most common grade 3/4 event (n = 12, 32%). Conclusions: Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Data from Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i>, <i>2</i>, or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
- Date Crossref
- 14/04/2023
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Pennsylvania pays non établi dans la noticeUniversité ou école supérieure
-
Dana-Farber Cancer Institute pays non établi dans la noticeStructure de recherche
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
Sidney Kimmel Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Center for Cancer Research pays non établi dans la noticeStructure de recherche
-
Center for Information Technology pays non établi dans la noticeStructure de recherche
-
Frederick National Laboratory for Cancer Research pays non établi dans la noticeStructure de recherche
-
City Of Hope National Medical Center pays non établi dans la noticeÉtablissement de santé
-
Catholic Health Initiatives pays non établi dans la noticeÉtablissement de santé
-
University of Kentucky pays non établi dans la noticeUniversité ou école supérieure
-
Southwestern Medical Center pays non établi dans la noticeÉtablissement de santé
-
The University of Texas Southwestern Medical Center pays non établi dans la noticeÉtablissement de santé
University of Pennsylvania, Dana-Farber Cancer Institute et University of California, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.